List of Contents

Genomic Biomarker Market Size, Share, and Trends 2024 to 2033

Genomic Biomarker Market (By Type: Predictive Biomarkers, Prognostic Biomarkers; By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Others; By End-User: Hospitals, Diagnostic Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 2231
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genomic Biomarker Market 

5.1. COVID-19 Landscape: Genomic Biomarker Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genomic Biomarker Market, By Type

8.1. Genomic Biomarker Market, by Type, 2024-2033

8.1.1 Predictive Biomarkers

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Prognostic Biomarkers

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Genomic Biomarker Market, By Disease Indication

9.1. Genomic Biomarker Market, by Disease Indication, 2024-2033

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Cardiovascular Diseases

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Neurological Diseases

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Renal Disorders

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Genomic Biomarker Market, By End-User 

10.1. Genomic Biomarker Market, by End-User, 2024-2033

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Diagnostic Centers

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Genomic Biomarker Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.3. Market Revenue and Forecast, by End-User (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2021-2033)

11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2021-2033)

11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-User (2021-2033)

Chapter 12. Company Profiles

12.1. Almac Group

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cancer Genetics Inc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eurofins Scientific

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Thermo Fisher Scientific Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Aepodia SA

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Epigenomics AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. US Biomarkers Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Roche Diagnostics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Myriad Genetics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Bio-Rad Laboratories

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global genomic biomarker market size was accounted at USD 5.32 billion in 2023 and it is expected to reach around USD 10.33 billion by 2033.

The global genomic biomarker market is poised to grow at a CAGR of 6.89% from 2024 to 2033.

The major players operating in the genomic biomarker market are Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics, Myriad Genetics, Bio-Rad Laboratories

Increase in the development of clinical laboratory tests and technological advancement, as well as due to an increase in the incidence of ovarian and gastric cancer, the demand for genomic biomarker-based medicine, and the burden of chronic diseases increases these are driving the growth of the genomic biomarker market.

North America region will lead the global genomic biomarker market during the forecast period 2024 to 2033.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us